Sequence verification for an obscure compound: how it is done — what changed since posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
The reason Sequence verification keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
Collapsed as off-topic by two members at trust level 3 or above
Reading back through, this was answered upthread and I missed it. My fault.
Taking post #32 at face value and following it one step further.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Coming back to post #34, because the follow-up matters more than the original answer.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
Sequence verification is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
This follows post #37 rather than contradicting it.
Reading back through the Sequence verification threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
That is a description of practice, not a recommendation of it.
Confirming post #37 from a second method, which matters more than confirming it from a second person.
Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.
I have kept the units in throughout, for the obvious reason.
Distinguishing three things in the Sequence verification discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Collapsed as off-topic by two members at trust level 3 or above
Everything in post #40 holds. The case it does not cover is the one I have.
Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is almost never consulted here.
Building on post #41 rather than restating it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Sequence verification would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
The arithmetic in post #43 is right; the assumption feeding it is the part to check.
Adding a null result on Sequence verification. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.
If anyone has run this properly I would rather read that than my own guess.
Collapsed as off-topic by two members at trust level 3 or above
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
Having read the whole Sequence verification thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it.
My understanding of Sequence verification is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
Post #52 describes the usual case. This is about the unusual one.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
One case, stated as one case.
Adding the measurement that post #55 says would settle it.
Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.
Two sentences on Sequence verification and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
One more caveat and then I will stop qualifying: the sample selected itself.
Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.
Take it as a starting point and not as a specification.